Flot.bio x Philip Hemme

Stephane Bancel, CEO of Moderna, discusses his journey from leading a biotech startup to spearheading advancements in mRNA therapeutics. He emphasizes the crucial role of team dynamics and company culture in biotechnology success. Bancel elaborates on the cutting-edge innovations in mRNA technology and how AI has transformed drug development at Moderna. He also shares insights on the vibrant biotech community in Cambridge and reflects on the challenges and leadership lessons faced in the industry.

We’re online with Chris Martin, COO of the 6th most valuable biotech in Europe, Verona Pharma. Their amazing story sees them bring a fully-owned respiratory drug to market and multiply its valuation by 120x within the last 5 years (from $50M to $6B today) 💸We talk about the commercial rollout of Ohtuvayre, Verona’s drug. We also discuss the British roots of the company and why execution is the most important in biotech.⭐️ ABOUT THE SPEAKERChris Martin joined Verona Pharma as their COO in 2020. He’s at the helm of Verona’s commercial strategy, driving the company’s progress in respiratory medicine. Before Verona, Chris played a key role as Executive Director of Marketing at SK Life Science, where he helped launch the CNS treatment XCOPRI® (cenobamate tablets). He also led the marketing efforts at Cempra, guiding the launch of their first product, and spent a decade at Salix Pharmaceuticals, where he led the Xifaxan® marketing team through its acquisition by Valeant Pharmaceuticals.🔗 LINKS MENTIONED- Verona Pharma’s corporate presentation: https://www.veronapharma.com/wp-content/uploads/2025/04/VRNA-Presentation-May-2025.pdf- Verona website: [http://veronapharma.com](http://veronapharma.com/)- Ohtuvayre website: [http://ohtuvayre.com](http://ohtuvayre.com/)- Q1 2025 results: https://www.veronapharma.com/news/verona-pharma-reports-first-quarter-2025-financial-results-and-provides-corporate-update/- Royalty pharma website: [https://www.royaltypharma.com](https://www.royaltypharma.com/)- Adrian Rawcliffe, Adaptimmune 🇬🇧 | Tecelra, TCR Cell Therapy | E22: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/- Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14: https://flot.bio/episode/bahija-jallal-immunocore/- The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/chris-martin-verona-pharma-copd/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:04] Commercial rollout of Ohtuvayre- [00:06:42] Fierce competition in COPD- [00:10:34] UK origins of Verona Pharma- [00:21:24] Strong Clinical data for Chronic Disease Patients- [00:26:01] Reaching Profitability for Verona Pharma- [00:30:58] Chris Martin Joining Verona Pharma- [00:34:51] Execution is Key to Success in Biotech- [00:42:48] How to get to the top in Biotech without a background in science- [00:46:33] Royalty model in Biotech- Quickfire

We’re online with Daniela Marino, CEO and co-founder of one of the best companies in Europe for tissue therapeutics, CUTISS.We discussed the story behind CUTISS and its current series C fundraising. We also discussed cell therapy in general and why kids are good at preventing burnout.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.🔗 LINKS MENTIONED- CUTISS Homepage (technology, about us): [https://cutiss.swiss](https://cutiss.swiss/)- CUTISS Deck Series C: https://cutiss.swiss/wp-content/uploads/2025/03/CUTISS-AG-Teaser-Q1-2025_Series-C.pdf- Thomas Ybert, DNA Script 🇫🇷 | DNA Printing & Synthesis | E27: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/- Ingmar Hoerr, CureVac | Founding a €20B Biotech | E03: https://flot.bio/episode/ingmar-hoerr-curevac-founding-a-20b-biotech-and-almost-dying-as-ceo/- Giammaria Giuliani profile https://www.forbes.com/profile/giammaria-giuliani/- Hansjorg Wyss profile - [https://en.wikipedia.org/wiki/Hansjörg_Wyss](https://en.wikipedia.org/wiki/Hansj%C3%B6rg_Wyss)📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:41] Story of CUTISS[00:04:47] Positive Phase 2 Data[00:16:03] Raising a Series C[00:26:34] Next steps for CUTISS[00:31:46] Cell Therapy and Tissue Therapy landscape[00:42:36] US Biotech Market[00:45:12] TechBio, Hardware and Automation[00:50:58] Kids preventing burnout[00:54:18] Daniela Marino, Academic and Female Founder[01:01:10] Quickfire

We’re in Barcelona 🇪🇸  with Joris Pezzini from Alira Health to discuss the hottest biotech insights right now, including obesity, I&I, radiopharmaceuticals and ADCs.---This episode is sponsored by Alira Health, an advisor and clinical development partner for life sciences companies. Learn more at https://bit.ly/alirahealth-flotbio-1---⭐️ ABOUT THE SPEAKERJoris Pezzini has been in the biotech world for over 15 years. Before joining Alira Health in 2019, he had worked in some top pharma and biotech companies across the US, UK and France, including UCB, LFB, and Bionest Partners. Through this combo of roles as a Biopharma executive in start-ups, mid-sized, pharma, and consulting firms, Joris has a good eye on the industry with a wealth of experience and knowledge.🔗 LINKS MENTIONED- Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset: https://www.fiercebiotech.com/biotech/roche-fattens-obesity-pipeline-paying-zealand-165b-upfront-co-develop-amylin-asset- Medicine 3.0: What It Is and Why You Need It - Hone Health: https://honehealth.com/edge/medicine-3-0-peter-attia/- Why ADCs and Radiopharmaceuticals Are Big Pharma’s New Obsession: https://flot.bio/adcs-radiopharmaceuticals-alira-health/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/joris-pezzini-alira-health-biotech-trend/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:17] Hottest biotech industry trends according to Joris Pezzini- [00:11:14] Medicine 3.0- [00:13:22] ADCs and Radiopharmaceuticals- [00:17:00] The “end” of the blockbuster model- [00:20:35] Challenges to raise money- [00:27:41] Transatlantic & China- [00:33:04] The success story of Alira- [00:44:50] Investing in real-world evidence and AI- [00:48:53] Background in bioprocessing- [00:58:20] Bridging biotech and healthy lifestyle- [01:05:42] Quickfire

We’re in Copenhagen 🇩🇰 with Christophe Bourdon, the CEO who turned a 116-year-old biopharma company from the brink of failure to success.We discuss the lessons behind the turnaround, innovation in dermatology, especially biologicals and I&I, and living in eight different countries.⭐️ ABOUT THE SPEAKERChristophe Bourdon came to be CEO of LEO Pharma in 2022, where he was tasked with the massive assignment of transforming the financially failing company into a success. Luckily, he had gained experience in roles of increasing leadership importance in many EU biotech companies, Sanofi, Amgen, and Alexion, as well as leading the smaller biotech, Orphazyme A/S, as their CEO. No,w Leo Pharma is in the green.🔗 LINKS MENTIONED- Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09: https://flot.bio/episode/marc-de-garidel-abivax-exit/- Jens Nielsen, BII | How to make translation of life science research work | E12: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/- On the Origin of Species: Charles Darwin: https://tinyurl.com/2nbhkecs- Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma: https://www.fiercebiotech.com/biotech/gilead-roars-jpm25-250m-upfront-research-deal-leo-pharma- Homepage LEO Pharma, history and pipeline: http://leo-pharma.com/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:01:54] Turnaround of LEO Pharma[00:08:47] Current products at LEO Pharma[00:17:28] STAT6 Protein Degrader, deal with Gilead[00:23:34] Immunology & Inflammation is hot[00:28:26] Pipeline of LEO Pharma & Dealmaking[00:38:20] Finance & IPO[00:45:03] Living & working in 8 countries[00:48:17] Quickfire

We’re in Munich 🇩🇪 with Cristoph Broja, Partner at EQT Life Sciences, the top venture capital firm in Europe.We talk about his lessons up until becoming a partner at the firm. We also talk about how to invest in hot areas such as obesity or ADCs, and the importance of being curious. ⭐️ ABOUT THE SPEAKERCristoph Broja has been a Partner at EQT Life Sciences since 2022. Prior to this, he found himself in a myriad of biotechs, such as being part of the investment team of the Boston-based Gurnet Point Capital, as well as B-Flexion Capital in London.🔗 LINKS MENTIONED- Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19: https://flot.bio/episode/dominik-schumacher-tubulis/- Claudia Ulbrich, Cardior 🇩🇪 | Being the Founder of a Rare €1B Exit | E15: https://flot.bio/episode/claudia-ulbrich-cardior/- René Kuijten, Head of EQT Life Sciences, on BioStock: [https://www.linkedin.com/posts/rené-kuijten-b503a1_collaboration-startups-investors-ugcPost-7293582558116663297-9Q-M](https://www.linkedin.com/posts/ren%C3%A9-kuijten-b503a1_collaboration-startups-investors-ugcPost-7293582558116663297-9Q-M?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAXuQREBNiVcFS8XPp62vaHeZfMBR6F5yK0)📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/christoph-broja-eqt-vc/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:01:51] Becoming partner at EQT Life Sciences- [00:02:48] Getting to the top in biotech without a life science degree- [00:10:40] Moving back to Europe- [00:13:19] Investments in ADCs, Tubulis, Cardior- [00:28:28] LSP 7, biggest venture fund in Europe- [00:35:07] Observing the Chinese biotech scene very closely- [00:39:05] Marriage between LSP and EQT- [00:48:41] Focus on M&A vs IPO- [00:59:17] Quickfire

We’re in Munich with Philipp Baaske, one of the best life science tool founders in Europe.We talked about the lessons of building this life science tools business, specialized in protein interactions. We also talked about the difficulties and rewards of entrepreneurship and the impact of life science tools.___This episode is sponsored by NanoTemper Technologies, which performs protein characterization. Learn more at https://bit.ly/flotbio_nanotemper___⭐️ ABOUT THE SPEAKERPhilipp Baaske, a German biophysicist, co-founded NanoTemper Technologies in 2008 with Stefan Duhr. He earned his PhD from Ludwig-Maximilians-University Munich, specializing in biophysics. Baaske pioneered MicroScale Thermophoresis, advancing drug discovery research. He was Co-CEO for 16 years before becoming Executive Chairman in 2024. An award-winning innovator, he supports biotech and entrepreneurship as a business angel.🔗 LINKS MENTIONEDAbout Nanotemper - https://nanotempertech.com/about/Thomas Ybert, DNA Script 🇫🇷 | DNA Printing & Synthesis | E27 - https://youtu.be/tF25lyAPUGI📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/philipp-baaske-nanotemper-boostrapping-biotech/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS[00:02:01] Bootstrapping NanoTemper[00:06:30] The science behind NanoTemper[00:17:55] Venture capital or not[00:24:44] I’ve never had a job[00:28:40] Impact of Biotech on Cancer[00:33:40] Importance of Europe[00:43:00] Chinese expansion[00:47:26] Manufacturing in house[00:50:41] Next 10 years[01:07:38] Quick fire

We’re online 🇸🇪 with Mathias Uhlen, one of the best entrepreneurial scientists in Europe.We talked about the entrepreneurial mindset in academia. We also talked about AI for biology and why he doesn’t believe in the current anti-ageing drugs.⭐️ ABOUT THE SPEAKERLooking at the career of Mathias Uhlen can only leave you feeling impressed. He has co-founded or invested in 26 startups while having published over 800 papers, and creating the Human Protein Atlas, one of the most successful biology projects ever. He was also the Founding Director of Science for Life Laboratory (SciLifeLab), a national project with the Swedish government to help technology and data-driven research in support of European life science research. 🔗 LINKS MENTIONED- New innovation award celebrates entrepreneurs who have taken on big challenges: https://www.kth.se/en/om/nyheter/centrala-nyheter/nytt-innovationspris-hyllar-entreprenoren-som-tar-sig-an-stora-utmaningar-1.1049278- Jens Nielsen, BII | How to make translation of life science research work | E12: https://flot.bio/episode/jens-nielsen-translation-of-life-science-research/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/mathias-uhlen-entrepreneur/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:05] How Mathias Uhlen co-founded 26 startups- [00:10:55] Entrepreneurial mindset- [00:15:10] Entrepreneurial scientist in Europe- [00:18:43] Developing tools for research in biotech- [00:20:53] Human Protein Atlas- [00:24:55] AI for biology and AlphaCell- [00:34:35] Lessons for younger academics- [00:37:24] Combination of tech and biology- [00:40:57] False promises of anti-ageing- [00:44:48] Quickfire- [00:48:35] Thanks for listening

We’re online 🇫🇷 with Thomas Ybert, the co-founder of DNA Script, the leading biotech for DNA printing of oligos. We talked about the commercialization of the first DNA printer. We also talked about company building at large and how to expand to the US successfully. ⭐️ ABOUT THE SPEAKER At just 30 years old, Thomas Ybert co-founded DNA Script in 2014 in Paris. Previously he worked in R&D at Sanofi before joining Total in the New Energies Division where he contributed to the bio jet-fuel project in collaboration with Amyris. It was here he developed his passion for manufacturing synthetic DNA which moved him from the world of academic research to a startup. 🔗 LINKS MENTIONED From 3 nucleotides to being a cornerstone technology for precision medicine, my journey creating an Enzymatic DNA Synthesis technology and company: https://www.linkedin.com/pulse/from-3-nucleotides-being-cornerstone-technology-precision-ybert-ykw3c?trackingId=HIpMVK4lTiOPcxcWeSsI4w%3D%3D&lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BIW0XygKqT4Wbnq6s0mNP7Q%3D%3D DNA Script to Unveil Industry’s Most Versatile On-site, On-Demand DNA Printer at the World’s Largest Synthetic Biology Conference: https://www.biospace.com/dna-script-to-unveil-industry-s-most-versatile-on-site-on-demand-dna-printer-at-the-world-s-largest-synthetic-biology-conference DNA Script Appoints Marc Montserrat as CEO to Drive Long-Term Commercial Growth for Groundbreaking Enzymatic DNA Synthesis Platform: https://www.dnascript.com/press-releases/dna-script-appoints-marc-montserrat-as-ceo-to-drive-long-term-commercial-growth-for-groundbreaking-enzymatic-dna-synthesis-platform/ Towards Longer, Purer Oligonucleotides Thanks to Enzymatic DNA Synthesis: https://www.synbiobeta.com/read/towards-longer-purer-oligonucleotides-thanks-to-enzymatic-dna-synthesis 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmH LinkedIn: https://www.linkedin.com/company/flot-bio/ X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:06] One decade after the inception of DNA Printing [00:12:35] The problem DNA printing is solving [00:22:44] Reaching €20M sales [00:25:09] Productizing a science breakthrough [00:32:49] Thomas Ybert's transition from CEO to CSO [00:39:53] Early US expansion for DNA Script [00:49:22] Next steps for DNA Script [00:51:18] Quickfire [00:57:50] Thanks for listening

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech. — — —Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots: https://www.turbine.ai/jpm25-event-registration— — —⭐️ ABOUT THE SPEAKERGunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail. 🔗 LINKS MENTIONED- - The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024- Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study- Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/- The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.⏰ TIMESTAMPS [00:00:00] Intro[00:02:24] Leqembi and BioArctic [00:10:40] Side effects of Leqembi for Alzheimer's treatment[00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments[00:21:00] Market access for Leqembi in Europe[00:27:03] Gunilla Osswald's commitment to patients[00:31:55] Leaving AstraZeneca, transitioning to biotech[00:38:42] Unique culture at BioArctic[00:42:26] Alzheimer's field in Europe and at large[00:48:20] Quickfire[00:53:42] Thanks for listening